CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for DGI Resolution, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

DGI Resolution, Inc.
Sturlugata 8
Phone: +354 570 1900p:+354 570 1900 Reykjavik, IS-101  Iceland Ticker: DCGNQDCGNQ
This company ceased filing statements with the SEC on 7/7/2010.
DGI Resolution, formerly deCODE genetics, Inc., completed the sale of its Iceland-based subsidiary, deCODE genetics ehf (also known as Islensk erfdagreining), and its drug discovery and development programs to a private company on 1/21/2010.
This Company's Plan of Liquidation went into effect on 6/10/2010.
This company is no longer actively traded on any major stock exchange.
Business Summary
DGI Resolution, Inc., formerly known as deCODE genetics, Inc. (deCODE), is a bio-pharmaceutical company developing and marketing products for the treatment, diagnosis, and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in therapeutic areas, and applies its discoveries in human genetics to bring to market deoxyribonucleic acid (DNA)-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. In November 2009, the Company announced that it had filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware. In January 2010, the Company completed the previously announced sale of its Iceland-based subsidiary, deCODE genetics ehf (also known as Islensk erfdagreining) and its drug discovery and development programs to Saga Investments LLC.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 IRA CQ
Score		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating		 Morningstar
Rating
-Yes-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200912/31/2008YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer KariStefansson 60 12/1/1999 8/1/1996
Chief Financial Officer, Treasurer LanceThibault 42 6/1/2001 6/1/2001
Senior Vice President - Drug Discovery and Development MarkGurney 54 2/1/2005 10/1/2000
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
MediChem Life Sciences, Inc. c/o deCODE Chemistry Woodridge IL United States

Business Names
Business Name
DCGNQ
deCODE biostructures, Inc.
deCODE Cancer ehf.
10 additional Business Names available in full report.

General Information
Number of Employees: 331 (As of 12/31/2008)
Outstanding Shares: 61,760,805 (As of 7/31/2009)
Shareholders: 4,008
Stock Exchange: OTC
Federal Tax Id: 43326704
Fax Number: +354 570 1903
Email Address: ir@decode.is


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, January 20, 2020